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Summary 
Introduction of the B7-1 gene into murine tumor cells can result in rejection of the B7-1 trans- 
ductants  and,  in some cases,  systemic immunity to  subsequent  challenge with  the  nontrans- 
duced tumor cells.  These effects have been largely attributed to the function of B7-1  as a co- 
stimulator  in  directly  activating  tumor  specific,  major  histocompatibility  class  I-restricted 
CD8 + T  cells. We examined the role of B7-1 expression in the direct rejection as well as in the 
induction  of systemic immunity to a nonimmunogenic murine tumor. B-16 melanoma cells 
with high levels of B7-1 expression did not grow in C57BL/6 recipient mice, while wild-type 
B-16 cells  and cells with low B7-1  expression grew progressively within 21  d.  In mixing ex- 
periments with B7-1 hi and wild-type B-16 cells, tumors grew out in vivo even when a minor- 
ity of cells  were B7-1-.  Furthermore,  the occasional tumors that grew out after injection of 
100% B-16 B7-1 hi cells showed markedly decreased B7-1  expression. In vivo antibody deple- 
tions showed that NKI.1 and CD8 + T  cells,  but not CD4 + T  cells,  were essential for the in 
vivo rejection of tumors. Animals that rejected B-16 B7-1 hi tumors did not develop enhanced 
systemic immunity against challenge with wild-type B-16 cells. These results suggest that a ma- 
jor role of B7-1  expression by tumors is to mediate direct recognition and killing by natural 
killer cells.  With an intrinsically nonimmunogenic tumor, this direct killing does not lead to 
enhanced systemic immunity. 
E 
xperimentally induced animal tumors can be classified 
r as immunogenic and nonimmunogenic  (1).  Immuno- 
genic tumors are rejected after transplantation into synge- 
neic animals that had been previously immunized with irra- 
diated cells  of the same tumor.  Nonimmunogenic tumors 
are not rejected when similarly tested. 
Evidence suggests that rejection of immunogenic tumors 
is primarily mediated by T  cells (1), with both CD8 + CTL 
and CD4 + Th cells playing important roles (2,  3).  In gen- 
eral,  the  induction  and  activation of T  cells  requires  two 
signals from APC (for reviews see references 4--6). The first 
signal, the engagement of the TCR to its cognate peptide- 
MHC ligand, provides specificity. The second signal is pro- 
vided by costimulatory molecules expressed on APCs bind- 
ing  to  their  counterreceptors  on  the  T  lymphocyte  (4). 
Binding of the TCIK with peptide-MHC complexes in the 
absence  of costimulation  results  in  T  cell  inactivation  or 
"anergy,"  which  is  associated with  a  block of IL-2  gene 
transcription (7). 
Among  the  known  costimulatory  molecules,  the  B7 
family of membrane proteins appears to be the most potent. 
B7 is a member of the Ig superfamily (8), and it is expressed 
on the majority of APCs,  such as dendritic  cells,  activated 
macrophages, and activated B  cells.  The B7  costimulatory 
pathway involves at least two molecules, B7-1  (CD80)  (8) 
and B7-2 (CD86) (9-11). Both B7-1 and B7-2 can interact 
with  their  counterreceptors,  CD28  and  CTLA-4,  on  T 
cells (10-12). The importance of B7-1 as a costimulator in- 
volved in  generating  an  antitumor  immune  response  has 
been suggested by a number of in vivo experimental sys- 
tems (13-15). In these studies, B7-1-expressing tumor cells 
are rejected in syngeneic hosts, whereas unmodified tumor 
cells are not. These studies suggest that tumors may be ca- 
pable  of delivering antigen-specific signals  to  T  cells,  but 
may not deliver the costimulatory signals  necessary for full 
activation of T  cells.  The rejection of B7-1-expressing tu- 
mors has been proposed to be mediated by CD8 §  T  cells 
(13,  15) or CD4 § T  cells (14). 
The  binding  of the  TCR  to  its  peptide-MHC  ligand 
may be insufficient to activate T  ceils against nonimmuno- 
genic tumors such as B16 murine melanoma cells since MHC 
class I expression may be low in these tumors. Consequently, 
generation  of specific CTL activity may be inadequate  as 
compared to  that by other  high  MHC  class  I-expressing 
tumors. It is not clear, however, whether enhanced second 
signal  such  as increased  expression  of B7-1  costimulatory 
molecules expressed on APCs can compensate for the defi- 
ciency of first signal.  In this study, we have chosen B16 as a 
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effect of both the B7-1  level and the quantity of high B7- 
1-expressing tumor cells required to cause the rejection of 
nonimmunogenic  tumor  cells.  Furthermore,  we  explored 
the role of lymphocyte subsets in the rejection of high B7- 
1-expressing tumor cells. Our results suggest that both the 
presence and levels of B7-1  expression on B7-1-transduced 
B16  cells can affect tumor growth in vivo. Mixing experi- 
ments with B7-1 hi and B7-1-  B-16  cells further indicated 
that  B7-1  expression mediates  direct killing.  In  addition, 
NK cells and CD8 + cells, but not CD4 + T  cells, are essen- 
tial for the in vivo rejection of high B7-1-expressing non- 
immunogenic tumor cells. 
Materials  and Methods 
Tumor Cells.  The  F10  subline of B-16  melanoma cells was 
obtained from the National Institutes of Health, Division of Can- 
cer Therapy tumor repository. Tumor cells were cultured in vitro 
in RPMI  1640  media, supplemented with  10% FCS, penicillin/ 
streptomycin (50 U/ml), g-glutamine (2 raM), sodium pyruvate 
(1 raM), and nonessential amino acids (0.1 raM), and they were 
grown at 37~  5% CO 2. All cells were periodically tested for and 
found to be free ofmycoplasma contamination. 
Transduction orB-16 Cells with B7-I Molecule Using Retroviral 
Vector.  Transduction of routine B7-1  gene into B-16 was per- 
formed with the MFG retroviral vector system as described previ- 
ously (16). Briefly, in this vector, Moloney murine leukemia vi- 
rug long terminal repeat sequences are used to generate both a 
full-length viral tLNA (for encapsidation into virus particles) and 
a subgenomic mRNA (analogous to the Moloney routine leuke- 
mia virus env mtLNA) that is responsible for the expression of in- 
serted sequences.  The B7-1  gene-containing MFG were intro- 
duced into CRIP cells to a generate recombinant virus with an 
amphotropic host range. Transduction was performed as described 
previously (16). After transduction, the retroviral supernatant was 
removed, and the cells were grown in culture for an additional 3 d 
to allow for integration and expression  of the transferred DNA. 
The expression orB7-1 was demonstrated by flow cytometry us- 
ing CTLA-4Ig, a soluble genetic fusion between the extracellular 
domain  of CTLA-4  and  an  IgC ~/  chain  (12),  and  goat anti- 
human IgG1-FITC (Cappel Laboratories, Cochranville, PA). 
Tumor Growth Experiments.  The B-16 B7-1 + cells are cloned 
by limiting dilution for different levels of B7-1 expression as de- 
termined by flow cytometry. Live B-16 B7-1 + tumor cells with 
different levels of B7-1 expression and wild-type B-16 cells were 
injected into 10 C57 BL/6 mice subcutaneously at a dose of 106 
cells per mouse. In the second experiment, high B7-l-expressing 
B-16 tumor cells are mixed with wild-type B-16 cells in different 
proportions (0, 25, 50, 75, and 100%). Groups of eight C57BL/6 
mice were injected subcutaneously with a final dose of 106 cells 
per mouse.  Tumor growth was  measured regularly. Mice were 
immediately euthanized when tumor growth was observed. 
In  Vivo Antibody  Depletion Experiments.  In vivo antibody de- 
pletions have been described previously (17).  Briefly, depletions 
were started 1 wk before tumor inoculation. 10 C57BL/6  mice 
were used in each group, mAb GK1.5 (18) was used for CD4 de- 
pletions, rnAb 2.43  (19) was used for CD8 depletions, and mAb 
PK136  (20) was used for NKI.I  depletion. Ammonium sulfate- 
purified ascites  fluid (titered at >1:2,000  by staining of spleno- 
cytes on the FACS  |  [Becton Dickinson & Co., Mountain View, 
CA]) were  injected intraperitoneally (0.1  rnl per mouse)  every 
other day for the  1st wk and once per week after inoculation. 
Depletion of lymphocyte subsets  was assessed on the day of live 
tumor injection, and weekly thereafter by flow cytometric analy- 
sis of spleen cells stained with 2.43 or GK1.5 followed by FITC- 
labeled goat antibody to rat IgG (Southern Biotechnology Associ- 
ates, Birmingham, AL), or PK136 followed by FITC-labeled goat 
antibody to mouse IgG. For each time point of analysis,  >99% 
depletion of the appropriate subset was achieved with normal lev- 
els of the other subsets.  Depletion was terminated on the 21st  d 
after tumor inoculation. 
In  Vivo Protection Assays.  Cells  for  injection  were  harvested 
from in vitro culture by trypsinization after limited expansion and 
washed three times in serum-free HBSS. For vaccination, 1 mil- 
lion  live B7-1 hi  B-16  cells  were  injected  into  each  C57BL/6 
mouse.  For challenge,  various  doses  of wild-type B-16  tumor 
cells (106, 10 s, and 104) were injected 2 wk after vaccination. All 
injections were in a volume of 0.1 lnl given subcutaneously in the 
left (vaccine) or right (challenge) flank.  All experiments included 
10  mice per group,  and  each  experiment was  repeated at least 
once. Mice were monitored twice per week and killed after the 
tumor development. 
Results 
Level of B7-I  Expression Affects Tumor Growth.  To  gen- 
erate B7-1-expressing B-16 cells, we used the MFG retro- 
viral vector system to transduce the murine B7-1  gene into 
B-16  cells.  Cells with  different levels of B7-1  expression 
were obtained from clones generated through limiting di- 
lution, with B7-1  levels determined by flow cytometry. As 
shown  in Fig.  1,  two  independent B-16 B7-1 +  clones re- 
vealed different levels of B7-1  expression. These  cell lines 
exhibited  similar  growth  kinetics  in  vitro  as  well  as  in 
SC1D  mice  in  vivo  (data  not  shown).  When  the  same 
number of tumor cells (106 per mouse)  were injected sub- 
cutaneously into C57BL/6  mice, however,  cells with high 
levels of B7-1  expression failed to grow in any of the recip- 
ient mice (Fig. 2,  open squares).  In comparison, low B7-1- 
expressing  cells  (Fig.  2,  closed squares) or  wild  type B-16 
cells (Fig. 2, closed circle) continued to grow in all of the in- 
jected mice. Tumor growth in all these mice was progres- 
sive without any plateau or regression at later time points. 
These results suggest that only high levels of B7-1  expres- 
sion on nonimmunogenic  tumor cells can lead to their re- 
jection in vivo. 
Outgrowth  of B7-I-  Tumor  Cells  in a Mixed Population. 
Because of the documented role of B7-1  as a costimulator 
in the initiation of T  cell activation, the immunologic ef- 
fects of B7-1-transduced tumors have  been largely attrib- 
uted  to  the  enhancement  of priming  of  tumor-specific 
CD8 + CTL precursors. If this form of costimulatory activ- 
ity represented  the  major  effect of high  B7-1  expression, 
not  every  cell  would  need  to  express  B7-1  to  activate 
CD8 +  responses.  If B7-1  mediated  direct  target  recogni- 
tion, however,  then even a minority orB7-1-  cells in the 
population would result in tumor formation.  This distinc- 
tion  is  most  easily  made  with  mixing  experiments.  We 
mixed B7-1hl--expressing B-16  tumor cells with wild-type 
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Figure 1.  Variation of B7-1 expression in different clones by flow cy- 
tometry.  Individual clones of B-16 B7-1 + cells were isolated by fimiting 
dilution. The level of  B7-1 expression was determined by flow cytometry 
with CTLA-4Ig followed by goat anti-human IgG1-FITC (Cappel Labo- 
ratories). MC1 and MC2 represent two different clones of B7-1-express- 
ing B-16 cells. In contrast to wild-type B-16 ceils (  ), MC1 (  ...... ) 
showed the highest level of B7-1  expression, while  MC2 (  .......... ) dis- 
played an intermediate level of B7-1  expression. Staining of wild-type 
B-16 cells with CTLA-4Ig followed by goat anti-human IgGwFITC was 
similar to that with goat anti-human IgG1-FITC alone. 
B-16  cells  in  different  proportions  (0,  25,  50,  75,  and 
100%)  immediately  before  subcutaneous  injection.  Each 
C57BL/6 mouse was injected with a total dose of 106 cells. 
Fig. 3  shows the results of tumor growth in each group  of 
mice. Tumors grew within 3 wk in all of the mice injected 
with  0,  25,  50,  and  75%  B7-1hi-expressing  B-16  cells. 
Again, all tumor growth was progressive. In a repeat of the 
experiment  shown  in  Fig.  2,  tumors  grew  out  in two  of 
eight mice injected with B-16 B7-1 hi cells. When  the  ex- 
planted tumor cells were stained for B7-1,  decreased B7-1 
expression comparable to that in the B-16 B7-1 l~ clone was 
noted  in these  tumor  cells  (Fig.  4).  These  results  suggest 
that  there  is  a  direct  killing of B7-1 +  tumor  cells  in vivo 
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Figure 2.  Level of B7-1 expression affects tumor growth in vivo. Live 
MC1  (open squares), MC2 (closed  squares), and wild-type B-16 (dosed drde) 
tumor cells were injected into groups of 10 C57 BL/6 mice subcutane- 
ously at a dose of 106 cells per mouse. The mice were monitored for evi- 
dence of tumor growth by palpation and inspection twice per week. -5-, 
BI6 B7-1 (MC1); --IIt-, B16 wild type; -I1-, B16 B7-1 (MC2). 
and  that  bystander  B7-1hLexpressing  tumor  cells  do  not 
help in the rejection of even a minority of low or negative 
B7-1-expressing tumors. 
NK  Cells and CD8 §  T  Cells Are Essential for the Rejection 
of B7-1 + Tumors.  To determine the types oflymphocytes 
that are important for the rejection of B7-1 + tumor cells in 
our in vivo model, we performed in vivo antibody deple- 
tion experiments. Depletion of lymphocyte subsets was as- 
sessed on the day of tumor injection, and weekly thereafter 
by flow cytometric analysis of spleen cells. More than 99% 
depletion of the appropriate subset was achieved with nor- 
mal levels of the other subsets (data not shown). As shown 
in Fig.  5  A,  all the mice with CD8 +  T  cell or NKI.1  cell 
depletions  failed  to  reject  tumors.  In  comparison,  mice 
with  CD4 +  T  cell depletion did not grow  tumors.  These 
Figure 3.  Outgrowth of B7-1-negative tumor cells 
in a mixed population. High B7-1-expressing B-16 ru- 
mor ceils (MC1) were mixed with wild-type B-16 cells 
in  different  proportions  (0,  25,  50,  75,  and  100%). 
Groups of eight C57BL/6 mice were injected subcuta- 
neously with a final dose of 106 cells per mouse. Tumor 
growth was measured as described above. 
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Figure 4.  Decreased  B7-1 expresmon in explanted tumors. The explant 
tumors were minced and digested with collagenase. Individual cells were 
stained with CTLA-4 Ig followed by goat anti-human IgG1-FITC (Cap- 
pel Laboratories). B-16 B7-1 MC1 (  .......... ) and B-16 wt (  ) were 
used as positive and negative controls for B7-1 stainings. Explanted tumor 
cells (  ........ ) were derived from mice injected with 100% of  B-16 B7- 
1 MC1. Note the decreased level of B7-1 expression in explanted tumor 
cells compared to the original B-16 B7-1 (MC1) tumor ceils. Staining of 
wild-type B-16 ceils with CTLA-4 Ig followed by goat anti-human 
lgG  1-FITC was similar to that with goat anti-human IgG1-FITC alone. 
results suggest that CD8 + T  cells  and NKI.1  cells,  but not 
CD4 + T  cells are essential for the primary rejection of B7- 
1hi-expressing B16 tumor cells.  Furthermore,  as shown in 
Fig. 5 B,  1 wk after termination of NKl.1  depletion,  mice 
began to show a continuous regression of tumors that was 
complete within  10  d.  In comparison,  the  termination  of 
CD8 + T  cell depletion did not lead to the regression of tu- 
mors.  These  results  suggest that  NKI.1  cells  are  the  most 
potent mediator of regression of B7-1 hi expressing B-16 tu- 
mor cells. 
Immunization orB-16 B7-1 hi Tumor Cells Does Not Lead to 
Protection against Challenge with  Wild-type B-16 Tumor Cells, 
We performed tumor protection experiments to investigate 
if B-16 B7-1 hi tumor cells  can generate systemic immunity 
against challenge with wild-type B-16 tumor cells.  1 million 
live B7-1 hi B-16 tumor cells  were injected subcutaneously 
into C57BL/6 mice for vaccination. 2 wk later, vaccinated 
mice  were  challenged  with  different  doses  of wild-type 
B-16 tumor cells.  Our results  demonstrated no protection 
against challenge with wild-type B-16 tumor cells (data not 
shown).  Furthermore,  introduction of the HPV-16 E7 an- 
tigen  into B7-1-expressing B-16  tumor cells  also  did  not 
generate  systemic  immunity against  challenge with  HPV- 
16  E7-expressing  B-16  tumor  cells  (data  not  shown). 
These  results  suggest that a major role of B7-1  expression 
by tumors is  to  mediate  direct  recognition  and  killing  by 
NK cells,  and  that  this  direct killing  does not lead  to  en- 
hanced systemic immunity with an intrinsically nonimmu- 
nogenic  tumor  either  with  or without  the  presence  of a 
strong tumor rejection antigen. 
Discussion 
The  results  of these  studies  force  a  reassessment  of the 
role of B7-1  expression by tumor cells in inducing antitu- 
mor immunity.  While  it  has been  generally accepted that 
B7-1  expression  enhances  a  tumor's  ability  to  present 
MHC  class  I-restricted antigens  to CD8 + T  cells  through 
costimulation,  the  identity  of the  APCs for MHC  class  I 
tumor antigens has not been experimentally determined in 
B7-1-transduced tumor vaccines. We have shown that for 
other forms of whole-cell vaccines, bone marrow-derived 
cells,  not the tumor cell, are the exclusive APCs for MHC 
class I-restricted tumor antigens  (21).  The results presented 
here,  indicating  that  high B7-1  expression  by tumor cells 
confers direct NK and CD8 + T  cell-mediated killing,  sug- 
gests that enhanced release of antigen by the tumor for up- 
take and presentation by bone marrow-derived APCs may 
also be an important mechanism of immune response gen- 
eration by B7-1-transduced tumors. 
Although  we  showed  that  high  B7-1-expressing  B-16 
melanoma was rejected in vivo (Fig.  2),  Chen et al.  dem- 
onstrated  that  B7-1-transduced  B-16  cells  were  tumori- 
genic (22). The discrepancy between our data and those of 
Chen et al.  can be explained by serveral possibilities.  First, 
the level of B7-1  expression may be different between  the 
tumors  used  in  these  two  studies.  It is  possible  that B7-I 
expression was significantly higher in our B7-1-transduced 
B-16 tumor cells.  We have shown in Fig.  2  that different 
levels orB7-1  expression  in the  tumor cells have different 
outcomes in the tumorigenicity.  For example,  B-16 mela- 
noma  cells  with  intermediate  levels  of B7-1  expression 
were shown to be tumorigenic.  Second, the heterogeneity 
of high B7-1-expressing tumor cells within the whole tu- 
mor population injected may influence the outcome in tu- 
mor growth. We have shown that even small quantities  of 
wild-type  B-16  tumor  cells  mixed  with  high  B7-1- 
expressing tumor cells  can lead  to  tumor growth  in  mice 
(Fig. 3). Furthermore,  the explanted tumor cells from mice 
injected with 100% high expressing B16 cells demonstrated 
decreased  B7-1  expression  in  explanted  tumor  cells  (Fig. 
4). These data indicate that bystander high B7-1-expressing 
tumor cells  do not help  in the  elimination  of neighboring 
low or negative B7-1-expressing tumors.  The small quan- 
tity  of low  or negative  B7-1-expressing  B16  tumor  cells 
might eventually outgrow and form tumor nodules  in the 
injected mice. 
Certain  B7-1-expressing  MHC  class  II  +  tumors  have 
been shown to be rejected through the function of CD4 + 
T  cells  (14).  In our study, NK cells  and CD8 + T  cells,  but 
not  CD4 +  T  cells,  are  critical  in  the  in  vivo rejection  of 
high  B7-1-expressing  B-16  cells.  This  may be  related  to 
the fact that Bl6 tumor cells  do not express MHC  class  II 
molecules (data not shown). 
NKI.1  cells  are found to be important in the in vivo re- 
jection of high B7-1-expressing B16 tumor cells as demon- 
strated by our in vivo antibody depletion  experiment  (see 
Fig.  5).  This is somewhat an unexpected result since most 
previous in vivo studies mainly emphasized the importance 
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Figure 5.  Effect  of lymphocyte subset depletions on 
the tumor growth of B7-1hi--expressing  B-16. For each 
C57BL/6 mouse, 106 of B7-1hi-expressing  MCI were 
injected subcutaneously. (A) Tumor growth  with in 
vivo antibody depletions. Depletions were started 1 wk 
before tumor inoculation, mAb GK1.5 (18) was used 
for CD4 + T  cell depletion (open  triangles),  mAb 2.43 
(19) was used for CD8 + T cell depletion (open squares), 
and mAb PK136 (20) was used for NKI.1 cell deple- 
tion (closed triangles).  Mice without  lymphocyte subset 
depletions were  used as control  (open  circles). Tumor 
growth was measured regularly. (B) Tumor growth af- 
ter termination of in vivo antibody depletions. Termi- 
nation of antibody depletions is indicated by an arrow 
on day 0 (day 21 after tumor injection). 1 wk after ter- 
mination of depletion (day 28 after inoculation of tu- 
mor cells), mice that were  once treated with  NKI.1 
depletion (closed triangles) began to show regression of 
tumors. In contrast, the tumor continued to grow in 
those mice that were once treated with CD8 + T cell 
depletion (open squares).  10 mice were used per group, 
and each experiment was repeated at least once. 
ofCD8 + (13,  15) and CD4 + (14) T  lymphocytes in the re- 
jection of B7-1 +  tumors.  Nevertheless,  B16  tumors  have 
low MHC  class I expression, and NK cell sensitivity can be 
induced through loss of MHC  class I molecules(for review 
see reference 23).  NK cells may therefore be important in 
the killing of B16 tumor cells. 
The B7-1  expression in the B16 tumors may play a role 
in NK cell activation. At least a subset of NK cells expresses 
CD28  (24, 25). NK cells have been shown to interact with 
B7-1 molecules on tumor cells in in vitro models (24). For 
example,  YT2C2,  a  human  NK  leukemia  cell  line,  ex- 
presses CD28  and can spontaneously lyse both murine and 
human cell lines expressing B7-1 in vitro (24). The partici- 
pation of CD28/B7-1  interactions in NK-mediated cyto- 
toxicity has been demonstrated by the correlation of target 
sensitivity with  levels  of B7-1  expression  in  target  cells 
(24).  The  efficient lysis of B7-1-expressing target cells by 
NK cells, however, might require additional interactions of 
other  "adhesion"  molecules  with  their  respective ligands 
(24).  In  addition,  the  CD28  costimulatory  pathway  has 
been reported to be important in the proliferation and cy- 
tokine production of NK cells (25). 
The mechanism for NK cell-mediated lysis is not com- 
pletely  understood.  NK  cells  can  selectively  kill  trans- 
formed,  virus- and intracellular bacteria-infected cells (for 
review see reference 26). NK cells are also able to mediate 
rejection of bone  marrow  allografts (27).  The  specific re- 
ceptors used by NK cells for recognition and activation re- 
main poorly defined, but they probably include both trig- 
gering  and  inhibitory  molecules  (28,  29).  MHC  class  I 
expression  by  target  cells  inhibits  lysis  mediated  by  NK 
cells,  often  in  an  allele-specific fashion  (30).  It  has  been 
proposed that NK cell inhibitory receptors recognize com- 
plexes of class I molecules with cellular peptides that define 
self. Alteration of these selfpeptides could render these cells 
sensitive to NK lysis. The peptides that define "self' can be 
either specific (31)  or diverse (32),  depending on the sys- 
tems employed. 
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gets without restriction to the MHC  has important impli- 
cations in the  design of immunotherapeutic  strategies and 
vaccine development against tumors since a significant pro- 
portion of tumors has been found to express low or nega- 
tive expression of MHC  molecules. The loss of MHC  class 
I antigens has been observed in a wide range of tumors, in- 
cluding breast (33), lung (34),  ovary (35),  skin (36),  mela- 
noma  (37),  cervix  (38),  colon,  and  rectum  (39-44),  to 
name a few. It will be important to better understand how 
NK cells recognize and lyse tumor targets to design better 
strategies for enhancing antitumor responses against low or 
negative MHC  class I-expressing tumor cells. 
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